YBX1 and neoplasm: In castration-resistant prostate cancer (CRPC) cells, VER-155008 suppressed the expression of full-length androgen receptor (AR) and AR splice variant 7 (ARv7) through Y-box binding protein 1 (YB-1) inhibition, which makes it an attractive anti-tumor agent for treating CRPC [91,92].